Excellent results and flexibility with xenofree serum-free medium for lymphocyte culture!
Cell-based immunotherapy is at the forefront of cancer treatment. The most common type of cell-based immunotherapy to date is T-cell therapy (with CAR-T and TIL being the mainstream). The cells used in immunotherapy are generally cultured in a medium supplemented with human serum. The use of serum introduces variability in the process due to individual differences among donors, leading to inconsistencies in cell growth and characteristics. By removing this serum and simplifying the process, regulatory risks are reduced, and the associated logistical burdens are alleviated. Nutri-T eliminates the need for serum by replacing its essential components with specific proteins, lipids, and other small molecules. <Product Overview> ■ Xeno-free ■ Serum-free, no serum supplementation required ■ Compliant with ISO13408 ■ For research use only ■ Developed using cells from actual cancer patients ■ Excellent results with PBMC, TIL, and CAR-T ■ Outstanding results at low initial seeding density
Inquire About This Product
Related Videos
basic information
Benefits for Four Customers 〈Performance〉 ■ Excellent Fold Expansion ■ Superior survival rate and CD8+ expression rate ■ High transduction efficiency (%) for CAR-T applications 〈Flexibility〉 ■ Excellent results with healthy PBMCs, TILs, and CAR-T applications ■ Excellent results using cells derived from cancer patients ■ Outstanding results at low seeding concentrations 〈Safety〉 ■ Elimination of serum-related risks through serum-free conditions ■ Manufactured in compliance with ISO13408 guidelines ■ Robust shipping tests 〈Simplicity〉 ■ No need for serum raw materials, storage, or purchasing ■ Short lead times ensured by Nutri-T stock at our global facilities ■ Provision of our technical support and complementary products
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（9）
Download All Catalogs
News about this product（4）
Company information
Sartorius Stedim, established in 2007 through the merger of the German company Sartorius, founded in 1870, and the French company Stedim, is a pioneer in "Single-Use Technology (SUT)." As a company capable of providing comprehensive technical support to the pharmaceutical and biotechnology industries, its cutting-edge technology is highly regarded worldwide in the fields of scientific instruments and biotechnology.
